Iridium completes Aireon acquisition; Rocket Lab acquisition approved

What happened

Iridium reported Q3 2026 results, confirming the completion of its previously announced acquisition of Aireon, which had been targeted for July 2026. Separately, the pending acquisition of Iridium by Rocket Lab received approval from Iridium stockholders, marking a decisive step toward closing. The Rocket Lab transaction, not covered in the prior DeepValue report, shifts the investment thesis from operational execution and leverage management to deal completion and consideration terms. Iridium's stock is likely to trade based on the merger arbitrage spread rather than fundamental catalysts such as NTN Direct or EMSS renewal. Consequently, the prior WAIT rating and scenario analysis are no longer applicable.

Implication

The operative question becomes the deal spread: if the market prices Iridium below the merger consideration, there may be a modest arbitrage opportunity, but deal completion risk (regulatory, financing, etc.) must be assessed. With stockholder approval in hand, key remaining hurdles are regulatory clearances and Rocket Lab's ability to finance the transaction. Iridium's standalone fundamentals, including Aireon integration and EMSS renewal, are now secondary unless the deal breaks. Investors holding Iridium should review the merger agreement for termination clauses and potential competing bids. A conservative approach is to treat the stock as a cash-equivalent with deal-completion risk, and to avoid adding exposure based on pre-deal operational expectations.

Thesis delta

The prior WAIT thesis was based on monitoring Aireon integration and NTN Direct progress with a 3-6 month re-assessment window. With Aireon closed and Rocket Lab acquisition approved, the thesis shifts from operational execution to merger completion probability and consideration value. The standalone investment case is superseded; any new position should be evaluated strictly as a merger arbitrage or event-driven situation.